mito-Dendra2^hiHSCs are more quiescent and have greater reconstitution capacity than mito-Dendra2^loHSCs. (A) Relative expression of Cd34 and Procr (EPCR) normalized to B2m expression in mito-Dendra2^lo and mito-Dendra2^hi HSCs quantified by reverse transcription polymerase chain reaction (mean ± SD; n = 5 each). (B) Representative flow cytometric graphs of EPCR expression in mito-Dendra2^lo (left panel) and mito-Dendra2^hi (right panel) HSCs. (C) Frequency of EPCR^hi HSCs within mito-Dendra2^lo, mito-Dendra2^hi, and total HSC fractions (mean ± SD; n = 3 each). (D) Representative flow cytometric graph of mito-Dendra2 fluorescence intensity in EPCR^lo/− and EPCR^hi HSCs. (E) Median fluorescence intensity of mito-Dendra2 in EPCR^lo/− and EPCR^hi HSCs (mean ± SD; n = 3 each). (F) Representative flow cytometric plots showing the correlation between mito-Dendra2 fluorescence intensity and EPCR expression of HSCs. (G) Representative flow cytometric plots showing cell cycle profiles of mito-Dendra2^lo and mito-Dendra2^hi HSCs. (H) Frequency of G0 phase cells within mito-Dendra2^lo and mito-Dendra2^hi HSCs (mean ± SD; n = 4 each). (I) Monthly peripheral blood (PB) chimerism of mononuclear cells in Ly5.1 recipients transplanted with mito-Dendra2^lo or mito-Dendra2^hi ESLAM LSK cells (250 cells) and Ly5.1 competitor cells (2 × 10⁵ cells) over 4 months posttransplantation (mean ± SEM; n = 4 or 5 each). (J) BM chimerism of HSCs in the Ly5.1 recipients transplanted with mito-Dendra2^lo or mito-Dendra2^hi ESLAM LSK cells 4 months posttransplantation (mean ± SEM; n = 4 or 5 each). *P < .05, **P < .01, ***P < .001, ****P < .0001, Student t test.